

UNITED STATES PATENT AND TRADEMARK OFFICE

M

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING	G DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/698,962	10/3	0/2003	James R. Casciani	009103-009740US	8826
20350	7590	09/01/2004		EXAM	INER
		WNSEND AND	KREMER, MATTHEW J		
TWO EMBA		CENTER		ART UNIT	PAPER NUMBER
SAN FRANC	CISCO, CA	94111-3834		3736	

DATE MAILED: 09/01/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		\wedge \wedge \wedge
	Application No.	Applicant(s)
	10/698,962	CASCIANI ET AL.
Office Action Summary	Examiner	Art Unit
	Matthew J Kremer	3736
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed /s will be considered timely. I the mailing date of this communication. D (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on		
,-	action is non-final.	
3) Since this application is in condition for allowar		
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.
Disposition of Claims		
4) Claim(s) 1 is/are pending in the application.		
4a) Of the above claim(s) is/are withdraw	wn from consideration.	
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>1</u> is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) are subject to restriction and/o	r election requirement.	
Application Papers		
9)☐ The specification is objected to by the Examine		
10)☐ The drawing(s) filed on is/are: a)☐ acc		
Applicant may not request that any objection to the		
Replacement drawing sheet(s) including the correct		
11)☐ The oath or declaration is objected to by the Ex	caminer. Note the attached Office	Action or form PTO-152.
Priority under 35 U.S.C. § 119		
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 	s have been received.	
2. Certified copies of the priority document		
3. Copies of the certified copies of the prio		ed in this National Stage
application from the International Burea		ed
* See the attached detailed Office action for a list	of the certified copies not receive	5 u .
Attachment(s)	,	
1) Notice of References Cited (PTO-892)	4) Interview Summary	
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) 	Paper No(s)/Mail D	Date Patent Application (PTO-152)
Paper No(s)/Mail Date 10/30/03.	6) Other:	

Application/Control Number: 10/698,962 Page 2

Art Unit: 3736

DETAILED ACTION

Double Patenting

1. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

2. Claim 1 is rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 16 of U.S. Patent No. 5,782,237 to Casciani et al. (Casciani)(cited by Applicant). Claim 1 of Casciani claims a "method for measuring blood oxygen saturation, comprising the steps of: providing a sensor and a pulse oximeter; selecting a light source and a light detector...; optimizing a wavelength spectrum of light received by said light detector from said light source for an oxygen saturation reading less than 80 percent...; placing said sensor on a patient; and determining said blood oxygen saturation said sensor and said pulse oximeter."

Although the conflicting claims are not identical, they are not patentably distinct from each other because claim 1 of Casciani claims a method, which is narrower in scope than the present application. Claim 1 of Casciani meets all the limitations set out in

Application/Control Number: 10/698,962

Art Unit: 3736

claim 1 of the present application and it would be obvious that one who is practicing the method of claim 1 of Casciani is actually practicing the method of claim 1 of the present invention. Claim 16 of Casciani claims a "method for measuring blood oxygen saturation, comprising the steps of: providing a sensor and a pulse oximeter; selecting a light source and a light detector...; optimizing a wavelength spectrum of light received by said light detector from said light source for an oxygen saturation reading less than 80 percent...; placing said sensor on a patient; and determining said blood oxygen saturation using said sensor and said pulse oximeter". Although the conflicting claims are not identical, they are not patentably distinct from each other because claim 16 of Casciani claims a method, which is narrower in scope than the present application. Claim 16 of Casciani meets all the limitations set out in claim 1 of the present application and it would be obvious that one who is practicing the method of claim 16 of Casciani is actually practicing the method of claim 1 of the present invention.

Page 3

3. Claim 1 is rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 of U.S. Patent No. 5,421,329 to Casciani et al. (Casciani) in view of U.S. Patent 5,058,588 to Kaestle in view of U.S. Patent No. 5,575,285 to Takanashi et al. (Takanashi). Claim 1 of Casciani claims a "method for using a pulse oximeter to measure blood oxygen saturation, comprising the steps of: providing a sensor and a pulse oximeter; selecting a light source for said sensor...placing said sensor on a patient; and determining said blood oxygen saturation using said sensor and said pulse oximeter". Claim 1 does not claim the step of

Application/Control Number: 10/698,962 Page 4

Art Unit: 3736

selecting a light detector but does claim a sensor with a pulse oximeter. It is well known in the art that the art of pulse oximetry includes the selection of a light detector to detect the light transmitted through or reflected from tissue since oxygen saturation measurements are derived from the light detector signals. (column 1, lines 12-30 of Kaestle). Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to include the selection of a light detector as disclosed by Kaestle since oxygen saturation measurements are derived from the light detector signals. Claim 1 of Casciani claims the step of "optimizing a wavelength spectrum of said light source for an oxygen saturation reading less than 80 percent" but does not claim the step of "optimizing a wavelength spectrum of light received by said light detector from said light source for an oxygen saturation reading less then 80 percent". It is well known that when light sources are optimized for a particular wavelength spectrum, the light detector is similarly optimized to those light sources so that the measurements can be carried out in bright places. (column 3, lines 45-57 of Takanashi). Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to optimize the selection of the light detectors as disclosed by Takanashi since oxygen saturation measurements can then be carried out in bright places.

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

Art Unit: 3736

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 5. Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by U.S. Patent 6,623,248 to Sperinde. (cited by the Applicant). Sperinde teaches the steps of providing a sensor (catheter) and a pulse oximeter (2), selecting a light source (LEDS 4,6,8), and selecting a light detector (32). (Fig. 4 of Sperinde). Sperinde teaches the step of optimizing a wavelength spectrum of light for an oxygen saturation reading less then 80 percent in the form of selecting the appropriate equations and wavelengths for particular range of oxygen saturation readings. (Figs. 5A-5B of Sperinde).
- 6. Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by U.S. Patent 4,446,871 to Imura. Imura teaches the steps of providing a sensor (the optical fiber of Fig. 1 of Imura) and a pulse oximeter (Fig. 3 of Imura), selecting a light source (reference numeral 1 of Fig. 1 of Imura), and selecting a light detector (reference numeral 13 of Fig. 1 of Imura). Sperinde teaches the step of optimizing a wavelength spectrum of light for a particular oxygen saturation range. (column 9, lines 22-50 of Imura).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Matthew J Kremer whose telephone number is 703-605-0421. The examiner can normally be reached on Mon. through Fri. between 8:30 a.m. - 5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Max Hindenburg can be reached on 703-308-3130. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Matthew Kremer Assistant Examiner

Art Unit 3736

ERIC F. WINAKUR PRIMARY EXAMINER